SPINEART receives 510(k) clearance for SCARLET® AC-Ti anterior cervical cage

Spineart proudly announces the 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its SCARLET® AC-Ti secured anterior cervical cage.

The SCARLET® AC-Ti builds on a decade of experience with the SCARLET® system. The SCARLET® AC-Ti addition introduces new features such as the MIMETIX® morphometric profile, developed with digital models of the vertebrae to optimize the contact surface between implant and endplates. The system allows for fixation with screws and anchors.

The SCARLET® AC-Ti cervical cage utilizes Spineart’s proprietary Ti-LIFE technology1. Ti-LIFE technology, a proprietary additive manufacturing process, has a porous structure that closely mimics the trabecular bone structure.

“This approval underscores our commitment to innovation, continuously evolving our most successful products, such as the SCARLET® system” said Alessia Erlingher, Chief Commercial Officer at Spineart.

 

 

Related

Related items
Date - Category Illustration Title Excerpt
  • Corporate
26 September 2025 Plan-Les-Ouates & Zurich (CH) – Antwerp (BE) Spineart (www.spineart.com), a global medtech innovator in advanced spine surgery solutions, today announces a CHF 25 million capital increase backed...
  • Product
Spineart announces the full-market launch of its SCARLET® AC-Ti secured anterior cervical cage in the United States. Following 510(k) clearance in May 2024, SCARLET® AC-Ti has been extensively evaluated by...
  • BAGUERA® C
Spineart today announces that it has completed a planned interim analysis for its 2-level BAGUERA® C IDE study, which showed that BAGUERA® C, its innovative cervical disc prosthesis, met the...